A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.
Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.
Tempus will provide sequencing and analysis for glioblastoma patients in a clinical trial at Duke using engineered poliovirus as a treatment.
The multi-center precision medicine trial has matched approximately 700 patients to 24 treatment arms so far, but some arms appear to be falling short of their recruitment goal.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Geneticure has raised around $1.1 million to fund the study, which may very well be the largest prospective RCT for personalization of high blood pressure treatment.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.